Alan B. Lancz & Associates, Inc. Bristol Myers Squibb CO Transaction History
Alan B. Lancz & Associates, Inc.
- $94.4 Million
- Q4 2023
A detailed history of Alan B. Lancz & Associates, Inc. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Alan B. Lancz & Associates, Inc. holds 7,250 shares of BMY stock, worth $287,535. This represents 0.39% of its overall portfolio holdings.
Number of Shares
7,250
Previous 10,350
29.95%
Holding current value
$287,535
Previous $600,000
38.17%
% of portfolio
0.39%
Previous 0.69%
Shares
7 transactions
Others Institutions Holding BMY
# of Institutions
2,553Shares Held
1.49BCall Options Held
25.9MPut Options Held
20M-
Vanguard Group Inc Valley Forge, PA186MShares$7.38 Billion0.2% of portfolio
-
Black Rock Inc. New York, NY163MShares$6.45 Billion0.21% of portfolio
-
State Street Corp Boston, MA91.6MShares$3.63 Billion0.23% of portfolio
-
Jpmorgan Chase & CO New York, NY88.8MShares$3.52 Billion0.44% of portfolio
-
Capital International Investors Los Angeles, CA70.2MShares$2.78 Billion0.79% of portfolio
About BRISTOL MYERS SQUIBB CO
- Ticker BMY
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 2,126,160,000
- Market Cap $84.3B
- Description
- Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...